TLR4 mutation reduces microglial activation, increases Aβ deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease

Journal of Neuroinflammation

Volumn 8, Issue , 2011, Pages

  Song, Min ^a,b   Jin, JingJi ^a   Lim, Jeong Eun ^a   Kou, Jinghong ^a   Pattanayak, Abhinandan ^a   Rehman, Jamaal A ^a   Kim, Hong Duck ^c   Tahara, Kazuki ^a   Lalonde, Robert ^d,e   Fukuchi, Ken Ichiro ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^e UNIVERSITÉ DE ROUEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; CHEMOKINE; CYTOKINE; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MESSENGER RNA; MUTANT PROTEIN; TOLL LIKE RECEPTOR 4; AMYLOID PRECURSOR PROTEIN; TLR4 PROTEIN, MOUSE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FUNCTIONAL ASSESSMENT; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MAZE TEST; MICROGLIA; MONOCYTE; MOUSE; NERVE CELL STIMULATION; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; WILD TYPE; ANIMAL; ANIMAL BEHAVIOR; BRAIN; CYTOLOGY; DISEASE MODEL; GENETICS; HISTOLOGY; HUMAN; METABOLISM; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CHEMOKINES; COGNITION DISORDERS; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; MAZE LEARNING; MICE; MICE, TRANSGENIC; MICROGLIA; MUTATION; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 79961134149     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-8-92     Document Type: Article

References (36)

1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356. 10.1126/science.1072994, 12130773.
2. Bertram L, Tanzi RE. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci 2008, 9:768-778. 10.1038/nrn2494, 18802446.
3. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat Med 2006, 12:1005-1015.
4. Rivest S. Regulation of innate immune responses in the brain. Nat Rev Immunol 2009, 9:429-439. 10.1038/nri2565, 19461673.
5. Mandrekar-Colucci S, Landreth GE. Microglia and inflammation in Alzheimer's disease. CNS Neurol Disord Drug Targets 2010, 9:156-167.
6. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010, 140:805-820. 10.1016/j.cell.2010.01.022, 20303872.
7. Liu Y, Walter S, Stagi M, Cherny D, Letiembre M, Schulz-Schaeffer W, Heine H, Penke B, Neumann H, Fassbender K. LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide. Brain 2005, 128:1778-1789. 10.1093/brain/awh531, 15857927.
8. Stewart CR, Stuart LM, Wilkinson K, van Gils JM, Deng J, Halle A, Rayner KJ, Boyer L, Zhong R, Frazier WA, Lacy-Hulbert A, El KJ, Golenbock DT, Moore KJ. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 2010, 11:155-161. 10.1038/ni.1836, 2809046, 20037584.
9. Reed-Geaghan EG, Savage JC, Hise AG, Landreth GE. CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation. J Neurosci 2009, 29:11982-11992. 10.1523/JNEUROSCI.3158-09.2009, 2778845, 19776284.
10. Tahara K, Kim HD, Jin JJ, Maxwell JA, Li L, Fukuchi KI. Role of toll-like receptor signalling in A{beta} uptake and clearance. Brain 2006, 129:3006-3019. 10.1093/brain/awl249, 2445613, 16984903.
11. Jin JJ, Kim HD, Maxwell JA, Li L, Fukuchi KI. Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation 2008, 5:23. 10.1186/1742-2094-5-23, 2430555, 18510752.
12. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Dewachter I, Walter J, Klockgether T, Van Leuven F. Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. J Neuroinflammation 2005, 2:22. 10.1186/1742-2094-2-22, 1274341, 16212664.
13. Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, De Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 2008, 451:720-724. 10.1038/nature06616, 18256671.
14. Yan P, Bero AW, Cirrito JR, Xiao Q, Hu X, Wang Y, Gonzales E, Holtzman DM, Lee JM. Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci 2009, 29:10706-10714. 10.1523/JNEUROSCI.2637-09.2009, 2756291, 19710322.
15. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 2004, 13:159-170.
16. Stine WB, Dahlgren KN, Krafft GA, LaDu MJ. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem 2003, 278:11612-11622. 10.1074/jbc.M210207200, 12499373.
17. Lalonde R, Kim HD, Fukuchi K. Exploratory activity, anxiety, and motor coordination in bigenic APPswe + PS1/DeltaE9 mice. Neurosci Lett 2004, 369:156-161. 10.1016/j.neulet.2004.07.069, 15450687.
18. Lalonde R, Kim HD, Maxwell JA, Fukuchi K. Exploratory activity and spatial learning in 12-month-old APP(695)SWE/co+PS1/DeltaE9 mice with amyloid plaques. Neurosci Lett 2005, 390:87-92. 10.1016/j.neulet.2005.08.028, 16169151.
19. Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 2007, 10:1387-1394. 10.1038/nn1997, 17965659.
20. Kuperstein I, Broersen K, Benilova I, Rozenski J, Jonckheere W, Debulpaep M, Vandersteen A, Segers-Nolten I, Van Der WK, Subramaniam V, Braeken D, Callewaert G, Bartic C, D'Hooge R, Martins IC, Rousseau F, Schymkowitz J, De SB. Neurotoxicity of Alzheimer's disease Abeta peptides is induced by small changes in the Abeta(42) to Abeta(40) ratio. EMBO J 2010, 29:3408-3420. 10.1038/emboj.2010.211, 20818335.
21. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998, 95:6448-6453. 10.1073/pnas.95.11.6448, 27787, 9600986.
22. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539. 10.1038/416535a, 11932745.
23. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440:352-357. 10.1038/nature04533, 16541076.
24. Tomic JL, Pensalfini A, Head E, Glabe CG. Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis 2009, 35:352-358. 10.1016/j.nbd.2009.05.024, 2725199, 19523517.
25. Udan ML, Ajit D, Crouse NR, Nichols MR. Toll-like receptors 2 and 4 mediate Abeta(1-42) activation of the innate immune response in a human monocytic cell line. J Neurochem 2008, 104:524-533.
26. Fiala M, Zhang L, Gan X, Sherry B, Taub D, Graves MC, Hama S, Way D, Weinand M, Witte M, Lorton D, Kuo YM, Roher AE. Amyloid-beta induces chemokine secretion and monocyte migration across a human blood--brain barrier model. Mol Med 1998, 4:480-489. 2230332, 9713826.
27. Ito S, Sawada M, Haneda M, Ishida Y, Isobe K. Amyloid-beta peptides induce several chemokine mRNA expressions in the primary microglia and Ra2 cell line via the PI3K/Akt and/or ERK pathway. Neurosci Res 2006, 56:294-299. 10.1016/j.neures.2006.07.009, 16978723.
28. Smits HA, Rijsmus A, van Loon JH, Wat JW, Verhoef J, Boven LA, Nottet HS. Amyloid-beta-induced chemokine production in primary human macrophages and astrocytes. J Neuroimmunol 2002, 127:160-168. 10.1016/S0165-5728(02)00112-1, 12044988.
29. Passos GF, Figueiredo CP, Prediger RD, Pandolfo P, Duarte FS, Medeiros R, Calixto JB. Role of the macrophage inflammatory protein-1alpha/CC chemokine receptor 5 signaling pathway in the neuroinflammatory response and cognitive deficits induced by beta-amyloid peptide. Am J Pathol 2009, 175:1586-1597. 10.2353/ajpath.2009.081113, 2751555, 19729478.
30. Man SM, Ma YR, Shang DS, Zhao WD, Li B, Guo DW, Fang WG, Zhu L, Chen YH. Peripheral T cells overexpress MIP-1alpha to enhance its transendothelial migration in Alzheimer's disease. Neurobiol Aging 2007, 28:485-496. 10.1016/j.neurobiolaging.2006.02.013, 16600437.
31. Vincent VA, Selwood SP, Murphy GM. Proinflammatory effects of M-CSF and A beta in hippocampal organotypic cultures. Neurobiol Aging 2002, 23:349-362. 10.1016/S0197-4580(01)00338-4, 11959396.
32. Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 2006, 49:489-502. 10.1016/j.neuron.2006.01.022, 16476660.
33. Nichol KE, Poon WW, Parachikova AI, Cribbs DH, Glabe CG, Cotman CW. Exercise alters the immune profile in Tg2576 Alzheimer mice toward a response coincident with improved cognitive performance and decreased amyloid. J Neuroinflammation 2008, 5:13. 10.1186/1742-2094-5-13, 2329612, 18400101.
34. Richard KL, Filali M, Prefontaine P, Rivest S. Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1-42 and delay the cognitive decline in a mouse model of Alzheimer's disease. J Neurosci 2008, 28:5784-5793. 10.1523/JNEUROSCI.1146-08.2008, 18509040.
35. Scholtzova H, Kascsak RJ, Bates KA, Boutajangout A, Kerr DJ, Meeker HC, Mehta PD, Spinner DS, Wisniewski T. Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology. J Neurosci 2009, 29:1846-1854. 10.1523/JNEUROSCI.5715-08.2009, 2699573, 19211891.
36. Doi Y, Mizuno T, Maki Y, Jin S, Mizoguchi H, Ikeyama M, Doi M, Michikawa M, Takeuchi H, Suzumura A. Microglia activated with the toll-like receptor 9 ligand CpG attenuate oligomeric amyloid {beta} neurotoxicity in in vitro and in vivo models of Alzheimer's disease. Am J Pathol 2009, 175:2121-2132. 10.2353/ajpath.2009.090418, 2774075, 19834064.